Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Name: Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
Published: 2004
License: Public Domain

M.D. Anderson Cancer Center · 2004

ClinicalTrials.gov · Datasets · License: Public Domain · 2004

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, myelodysplastic syndrome, aml, high-risk myelodysplastic syndrome, mds, clofarabine, cytarabine, ara-c, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Related documents